Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anrukinzumab in active ulcerative colitis
NCT01284062Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2011
- Primary completion
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of anrukinzumab in ulcerative colitis (UC), sponsored by Pfizer. Started Mar 2011; status: completed.
02
Drugs
anrukinzumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01284062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01284062.